Background {#Sec1}
==========

Severe infection is the leading cause of non-scheduled hospital admission \[[@CR1]\]. Depending on the severity of infection mortality rate can be as high as 60% in septic shock patients \[[@CR2]\].

But consequences of severe infection extend well beyond the first month following it, with an increased mortality during at least the first year \[[@CR3]\].

Prognostic factors associated with sepsis are well studied by many authors, especially among the Intensive Care Unit (ICU) population, but even in this specific population they all refer to short term mortality (ICU \[[@CR4]\], hospital \[[@CR1], [@CR5]\]^,^ or 28-day mortality \[[@CR6]\]). Age \[[@CR4], [@CR7]\], comorbidities \[[@CR2], [@CR4]--[@CR6]\], severity of acute illness \[[@CR2], [@CR4], [@CR8]\], focus of infection \[[@CR2], [@CR4], [@CR6], [@CR9]\], place of acquisition (community, hospital or ICU-acquired) \[[@CR2], [@CR5]\] and infection by specific organisms \[[@CR2], [@CR4]\] have been nominated as potential risk factors in this sub-population.

Since many patients admitted to hospital with infection have important concomitant medical conditions that may influence long-term prognosis it seems important to study long-term mortality.

As far as we know there are no studies on long-term prognostic factors in general hospital patients with infection. The aim of the current study is to determine independent risk factors for 5-year mortality in hospitalized patients with severe infection.

Methods {#Sec2}
=======

Ethics statement {#Sec3}
----------------

This study was approved by the Institutional Review Board of Hospital de Santo António, Oporto Hospital Centre, Portugal, and informed consent was waived due to the observational nature of the study.

Study design and patient population {#Sec4}
-----------------------------------

Prospective cohort study conducted at a 600-bed tertiary care university hospital, over 1-year period (1st June 2008 to 31st May 2009). All consecutive adult patients admitted to the medical, surgical, nephrology or hematology wards of the hospital or to the intensive care unit (ICU) that had a diagnosis of infection were included, based on the Center for Disease Control (CDC) criteria \[[@CR10]\]. Infections were classified as community-acquired (CAI), healthcare-associated (HCAI) or hospital-acquired, according to the place of acquisition. Long term mortality was defined as mortality 5 years after the infection diagnosis.

Data concerning mortality was obtained from *SClinico Hospitalar*, an informatic tool connected to a national network that gathers healthcare information nationwide.

Definitions {#Sec5}
-----------

Severe infection was defined as an infection which led to hospital admission (with or without sepsis criteria).

CAI was defined as an infection detected within 48 h of hospital admission in patients who did not fit the criteria for a HCAI.

HCAI was defined using the same criteria of Deborah Friedman \[[@CR11]\], an infection present at the time of hospital admission or within 48 h of admission in patients that fulfilled any of the following criteria:received intravenous therapy at home, wound care or specialized nursing care through a healthcare agency, family or friends; or, self-administered intravenous medical therapy in the 30 day period before the onset of the infection;attended a hospital or haemodialysis clinic, or received intravenous chemotherapy in the previous 30 days;were hospitalized in an acute care hospital for 2 or more days in the previous 90 days;resided in a nursing home or long-term care facility.

HAI was defined as a localized or systemic condition that resulted from an adverse reaction to the presence of an infectious agent(s) or its toxin(s), and that occurred 48 h or more after hospital admission and was not incubating at the time of admission \[[@CR10]\]. Infections in patients recently discharged from the hospital within the previous 2-week period were also included in this group.

The CDC definitions were used to define infections at different anatomic sites \[[@CR10]\].

We grouped *Enterococcus faecium* vancomycin-resistant, methicillin-resistant *Staphylococcus aureus* (MRSA), extended-spectrum beta-lactamase (ESBL) producer *Escherichia coli (E. coli)* and *Klebsiella* species, *Klebsiella pneumoniae* Carbapenamase-hydrolyzing and multidrug resistant (MDR) *Acinectobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter* species in a group denominated ESKAPE \[[@CR12]\].

The presence of ESBL production among *E. coli* and *Klebsiella* spp. strains was screened by the automatic analyzer Vitek2 (BioMérieux). It was always confirmed by a disk diffusion test that detects synergism between the cephalosporins/monobactam and clavulanate. If the interpretation of the results was doubtful we also performed Etest®: the combination strains of cefotaxime and cefotaxime/clavulanate and ceftazidime and ceftazidime/clavulanate allows the detection of ESBL whenever the ratio antibiotic/antibiotic + inhibitor is equal or above 8.

The presence of carbapenemase production in Enterobacteriaceae was suspected whenever MIC's for ertapenem, imipenem and meropenem exceed 0.5, 1 and 1 μg/mL, respectively. In such cases, a modified Hodge test was performed, and the ultimate confirmatory test was carbapenemase detection by molecular methods.

The comorbidities studied included immunosuppression (administration of chemotherapy in the 12 months prior to hospital admission, either radiation therapy or administration of 0.2 mg/kg/day of prednisolone for at least 3 months prior to hospital admission, administration of 1 mg/kg/day of prednisolone for 1 week in the 3 months prior to hospital admission or infection with human immunodeficiency virus), chronic liver disease \[[@CR13]\], chronic heart failure \[[@CR13]\], chronic respiratory disease \[[@CR13]\], hematological disease \[[@CR14]\], cancer \[[@CR14]\], diabetes mellitus requiring insulin therapy or oral hypoglycaemic agents before the infection and/or atherosclerosis (defined as a previous history of a transient ischemic attack, stroke, angina, myocardial infarction or peripheral arterial disease).

Functional performance status was assessed by the Karnofsky index \[[@CR15]\]. A score of lower than 70 implies that the patient is unable to perform normal activities or do active work.

For the first day of antibiotic therapy, the acute physiological scores, The Simplified Acute Physiology Score (SAPS II) \[[@CR14]\] and Sepsis-related Organ failure Assessment (SOFA) were recorded \[[@CR16]\].

The initial empirical antibiotic treatment was considered "adequate" if the initial antibiotic prescribed within the 24 h matched in vitro susceptibility of a pathogen deemed to be the likely cause of infection and when the dosage and route of administration were appropriate for current medical status (focus and severity of infection); only patients with positive microbiology will be considered in this analysis.

Statistical analysis {#Sec6}
--------------------

Continuous variables are described as means and standard deviations (SD), categorical variables are described with absolute frequencies and percentages. Student T-tests or Mann-Whitney tests are used to compare continuous values between types of infection. For categorical variables these comparisons are performed using Pearson χ^2^ test.

Variables associated with long term mortality were studied through logistic regression. Variables studied through the multiple regression logistic model were: age, functional status (Karnofsky Index), diabetes, atherosclerosis, cancer, type of infection (community, healthcare associated or hospital acquired), severity of infection, SAPS II and SOFA scores calculated for the day of infection diagnosis, site of infection, microbiological documentation of infection, positive blood cultures, infection by a multidrug resistant pathogen or an infectious agent from the group ESKAPE and inappropriate antibiotic therapy. Those with a clear association in the univariate analysis (*p*-value \< 0.1) or considered clinically significant were selected for the multivariable analysis. The results of the multivariable models are expressed as odds ratio (OR) with 95% confidence interval (CI~95%~) and *p*-values. The accuracy of the models was assessed by the area under the receiver operating characteristics curve (AU-ROC) and calibration was tested using the Hosmer-Lemeshow goodness-of-fit test. The significance level was defined as *p* \< 0.05.

Data were analysed using SPSS, version 18 for Windows (Chicago, IL).

Results {#Sec7}
=======

There were 1035 records included in the initial study, 22 (2%) were excluded from the present analysis due to insufficient data regarding long-term outcome. Of the 1013 patients included, 86% (*n* = 868) were recruited in the ward and 14% (*n* = 145) in ICU.

Mean ± SD age of included patients was 65 ± 20 years and 51% were female (*n* = 517). Most of them, 65% (*n* = 661) had at least one comorbidity and 30% (*n* = 300) had more than one (Table [1](#Tab1){ref-type="table"}).Table 1General characteristics patients included in the study and its association with 5 year mortalityVariableTotalDead at 5 yearsCrude OR (95% CI)*p* valueAge, median ± SD, years65 ± 2074 ± 141.05 (1.04--1.05), per year\< 0.001Female, n (%)517 (51)190 (50)1.06 (0.82--1.37)0.656Underlying conditions, n (%) Diabetes mellitus198 (20)85 (22)1.33 (0.97--1.83)0.074 Atherosclerosis236 (23)127 (34)2.43 (1.80--3.27)\< 0.001 Immunosuppression219 (22)75 (20)0.84 (0.61--1.15)0.274  Chemotherapy35 (4)26 (7)  Radiotherapy8 (1)6 (2)  Long-term corticoid168 (17)46 (12)  Short-term corticoid22 (2)11 (3)  HIV positive (non-AIDS)6 (1)1 (0)  AIDS3 (0)2 (1) Chronic liver disease22 (2)14 (4)3.00 (1.25--7.22)0.014 Chronic heart failure74 (7)44 (12)2.64 (1.63--4.29)\< 0.001 Chronic respiratory disease66 (7)43 (11)3.40 (2.01--5.74)\< 0.001 Chronic kidney disease148 (15)56 (15)1.02 (0.71--1.46)0.908  End Stage kidney disease69 (7)23 (6)0.83 (0.49--1.39)0.469  Cancer45 (4)36 (10)7.29 (3.47--15.41)\< 0.001  Haematologic cancer59 (6)35 (9)2.59 (1.51--4.42)0.001No comorbidities352 (35)78 (21)0.34 (0.25--0.46)\< 0.001Karnofsky Index \< 70311 (31)195 (52)4.73 (3.56--6.29)\< 0.001Type of infection\< 0.001 Community483 (48)144 (38)1.0 Healthcare associated219 (22)106 (28)2.21 (1.59--3.07) Hospital-acquired311 (31)129 (34)1.67 (1.24--2.25)Severity of infection\< 0.001 Infection275 (27)86 (23)1.0 Sepsis355 (35)125 (33)1.19 (0.85--1.67) Severe sepsis292 (29)116 (31)1.45 (1.02--2.05) Septic shock91 (9)52 (14)2.93 (1.80--4.77)SAPS II score, per point29 ± 1335 ± 141.07 (1.06--1.09)\< 0.001SOFA score, per point2 ± 33 ± 31.11 (1.06--1.16)\< 0.001Focus of infection0.043 Respiratory407 (40)156 (41)1.0 Urinary339 (34)134 (35)1.05 (0.78--1.41) Abdominal209 (21)62 (16)0.68 (0.47--0.97) Other19 (2)14 (4)1.40 (0.81--2.43)Microbiologic documentation691 (68)276 (73)1.41 (1.07--1.87)0.015Positive blood cultures151 (15)70 (19)1.55 (1.09--2.19)0.014Infection by a MDR pathogen322 (51)146 (56)1.42 (1.03--1.95)0.031Infection by an ESKAPE pathogen113 (18)61 (24)1.88 (1.25--2.83)0.003Inappropriate antibiotherapy144 (21)73 (26)1.74 (1.20--2.52)0.003*CI* Confidence interval, *SD* Standard deviation, *HIV* Human immunodeficiency virus, *AIDS* Acquired immunodeficiency syndrome, *OR* Odds ratio

The most common foci of infection were respiratory, urinary and intra-abdominal (Table [1](#Tab1){ref-type="table"}). Overall isolation rate was 68% (*n* = 691) (Table [2](#Tab2){ref-type="table"}). Initial antibiotic therapy was inadequate in 18% (*n* = 179) of the patients included.Table 2Isolated infectious agentsIsolated microorganisms, n (%)TotalDead at 5 yearsCommunity-acquired infection272 (56)93 (65) *Escherichia coli*101 (10)39 (10) *Streptococcus pneumoniae*59 (6)18 (5) *Haemophilus influenza*17 (2)3 (1) *Proteus mirabillis*12 (1)5 (1) *Klebsiella pneumoniae*11 (1)5 (1) *Pseudomonas aeroginosa*10 (10)5 (1) *Enterococcus faecium*7 (0)4 (1) MSSA7 (0)2 (1) *Legionella pneumophyla*6 (0)0 (0) Other42 (4)21 (6) ESKAPE10 (10)5 (1) MDR79 (8)36 (10)Healthcare-associated infection160 (73)76 (72) *Escherichia coli*69 (7)29 (8) MSSA21 (2)9 (2) *Klebsiella pneumoniae*15 (2)6 (2) *Pseudomonas aeroginosa*11 (1)6 (2) *Enterococcus faecalis*9 (0)4 (1) MRSA8 (0)6 (2) *Proteus mirabillis*7 (0)4 (1) *Streptococcus pneumoniae*7 (0)5 (1) *Enterococcus faecium*6 (0)4 (1) Other31 (3)18 (5) ESKAPE30 (3)16 (4) MDR85 (8)44 (12)Hospital-acquired infection259 (833)107 (83) *Escherichia coli*68 (7)24 (6) *Pseudomonas aeroginosa*37 (4)18 (2) MRSA30 (3)18 (5) *Enterococcus faecalis*24 (2)9 (2) *Klebsiella pneumoniae*23 (2)7 (2) MSSA18 (2)3 (1) *Proteus mirabillis*17 (2)8 (2) *Enterobacter cloacae*16 (2)8 (0) *Acinetobacter baumanni*13 (1)4 (0) *Enterococcus faecium*13 (1)7 (2) *Candida albicans*7 (0)0 (0) *Morganella morganni*6 (0)1 (0) *Clostridium difficile*5 (0)3 (1) *Enterobacter aerogenes*5 (0)2 (1) *Serratia marcescens*5 (0)3 (1) Other24 (2)14 (4) ESKAPE73 (7)10 (3) MDR158 (16)79 (21)*MSSA* Methicillin-sensitive *Staphylococcus aureus*, *MRSA* Methicillin-resistant *Staphylococcus aureus*, *ESKAPE Enterococcus faecium,* MRSA*,* ESBL *Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa* and *Enterobacter* species; *MDR* Multidrug resistant bactéria

Severity of acute illness was documented by a median ± SD SAPS II and SOFA scores of 30 ± 13 and 2 ± 3, respectively. Hospital and 5-year mortality rates were 14% (*n* = 137) and 37% (*n* = 379), respectively.

Variables associated with 5-year mortality in the univariate analysis were: age, the presence of comorbidities, namely: diabetes, atherosclerosis, chronic liver disease, chronic heart failure, chronic respiratory failure, solid tumours and haematologic cancer, Karnofsky index\< 70, type of infection, severity of infection, SAPS II and SOFA scores, focus of infection, microbiologic documentation of infection, positive blood cultures, infection by a MDR pathogen or a pathogen from the group ESKAPE and inappropriate initial antibiotic therapy (Table [1](#Tab1){ref-type="table"}). The final model retained: age, cancer, absence of known comorbidities, Karnofsky index \< 70, SAPS II, positive blood cultures and infection by a pathogen from the ESKAPE group (Model 1, Table [3](#Tab3){ref-type="table"}). A second model without SAPS II and SOFA scores was built and the same variables were retained plus haematologic disease and severity of infection (Model 2, Table [3](#Tab3){ref-type="table"}). The AU-ROC curve was 0.81 (0.77-0.84) and 0.80 (0.76-0.83) for the first and second models, respectively (Fig. [1](#Fig1){ref-type="fig"}).Table 3Independent risk factors associated with long term death in patients admitted with severe infectionVariableTotalDead at 5 yearsAdjusted OR (95% CI)Model 1Model 2Age, mean ± SD, per year65 ± 2074 ± 141,03\
(1.02--1.04)1,04\
(1.03--1.05)Cancer, n (%)45 (4)36 (10)4.36\
(1.65-- 11.53)5.93\
(2.26-- 15.51)Chronic haematologic disease, n (%)59 (6)35 (9)2.37\
(1.14--4.93)No comorbidities, n (%)352 (35)78 (21)0.40\
(0.26--0.62)0.45\
(0.29--0.69)Karnofsky Index \< 70, n (%)311 (31)195 (52)2.25\
(1.48--3.40)2.32\
(1.54--3.50)Severity of infection, n (%) Infection275 (27)86 (23)1.00  Sepsis355 (35)125 (33)1.15\
(0.72--1.83) Severe sepsis292 (29)116 (31)1.33\
(0.81-- 2.17) Septic shock91 (9)52 (14)3.77\
(1.80-- 7.89)SAPS II, median ± SD, per point29 ± 1335 ± 141.05\
(1.03--1.07)Positive blood cultures, n (%)151 (15)70 (19)1.57\
(1.01--2.44)Infection by an ESKAPE pathogen, n (%)113 (18)61 (24)1.61\
(1.00--2.60)1.61\
(1.00--2.60)*OR* Odds ratio, *CI* Confidence interval, *ESKAPE Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa* and *Enterobacter* speciesFig. 1Area under the receiver operating characteristics (AU-ROC) curve (95% CI) for the final models. Model 1: all patients with acute severity scores (SPAS II and SOFA): 0.81 (0.77--0.84). Model 2: all patients without acute severity scores: 0.80 (0.76--0.83). Model 3: only patients that survived hospital admission: 0.77 (0.73--0.81)

A third model considering only patients that were discharged alive from the hospital was made and results are shown in Table [4](#Tab4){ref-type="table"}. The variables retained were: age, comorbidities (cancer, chronic respiratory disease and *diabetes mellitus*), karnofsky index\< 70 and positive blood cultures (Table [4](#Tab4){ref-type="table"}). The AU-ROC curve was 0.77 (0.73-0.81) (Fig. [1](#Fig1){ref-type="fig"}).Table 4Characteristics of the group of patients discharged alive and its association with 5 year mortalityVariableTotal\
(*n* = 876)Dead at 5 years\
(*n* = 243)Crude OR (95% CI)*p* valueAdjusted OR (95% CI)Age, median ± SD, years63 ± 2073 ± 141.04 (1.03--1.05), per year\< 0.0011.03, per year (1.02--1.05)Female, n (%)458 (52)132 (54)0.89 (0.66--1.20)0.454Underlying conditions, n (%) Diabetes mellitus183 (21)70 (29)1.86 (1.32--2.63)\< 0.0011.65 (1.06--2.56) Atherosclerosis283 (21)74 (31)2.11 (1.50--2.96)\< 0.001 Immunosuppression195 (22)51 (21)0.90 (0.63--1.29)0.575  Chemotherapy26 (3)17 (7)  Radiotherapy6 (1)4 (2)  Long-term corticoid166 (18)34 (14)  Short-term corticoid16 (2)5 (2)  HIV positive (non-AIDS)6 (1)1 (0)  AIDS2 (0)1 (0) Chronic liver disease14 (2)6 (3)1.98 (0.68--5.76)0.211 Chronic heart failure62 (7)33 (14)3.27 (1.94--5.52)\< 0.001 Chronic respiratory disease66 (7)43 (11,4)4.17 (2.39--7.26)\< 0.0012.27 (1.09--4.69) Chronic kidney disease138 (16)46 (19)1.37 (0.93--2.03)0.111 End Stage kidney disease66 (8)20 (8)1.14 (0.66--1.98)0.639 Cancer27 (3)18 (7)5.55 (2.46--12.53)\< 0.0014.69 (1.71--12.83) Haematologic cancer42 (5)18 (7)2.03 (1.08--3.81)0.028No comorbidities322 (37)48 (20)0.32 (0.23--0.46)\< 0.001Karnofsky Index \< 70230 (26)115 (47)4.05 (2.93--5.59)\< 0.0012.50 (1.63--3.83)Type of infection\< 0.001 Community436 (50)97 (40)1.0 Healthcare associated187 (21)75 (31)2.34 (1.62--3.39) Hospital-acquired253 (29)71 (29)1.36 (0.96--1.95)Severity of infection0.61 Infection255 (29)66 (27)1.0 Sepsis325 (37)96 (40)1.20 (0.83--1.73) Severe sepsis246 (28)70 (29)1.14 (0.77--1.67) Septic shock50 (6)11 (5)0.80 (0.39--1.67)SAPS II score, per point27 ± 1031 ± 91.05 (1.03--1.06)\< 0.001SOFA score, per point2 ± 22 ± 20.99 (0.93--1.06)0.771Focus of infection0.005 Respiratory345 (39)94 (39)1.0 Urinary304 (35)100 (41)1.31 (0.94--1.83) Abdominal280 (21)33 (14)0.60 (0.38--0.94) Other47 (5)16 (7)1.38 (0.72--2.64)Microbiologic documentation593 (68)179 (74)1.48 (1.07--2.06)0.020Positive blood cultures126 (14)46 (19)1.61 (1.09--2.40)0.0181.66 (1.04--2.64)Infection by a MDR pathogen265 (49)89 (53)1.24 (0.86--1.79)0.245Infection by an ESKAPE pathogen82 (15)30 (18)1.33 (0.81--2.17)0.256Inappropriate antibiotherapy113 (19)43 (24)1.55 (1.01--2.39)0.044*CI* Confidence interval, *SD* Standard deviation, *HIV* Human immunodeficiency virus, *AIDS* Acquired immunodeficiency syndrome, *OR* Odds ratio

Discussion {#Sec8}
==========

The 5-year mortality rate in our cohort was 37%. Previous articles have described a 5-year mortality between 39 and 74% \[[@CR17]--[@CR21]\]. This difference could be explained partially by the implementation of the *Surviving Sepsis Campaign* in 2004 that resulted in a consistent decrease in mortality due to severe infection/sepsis \[[@CR22]\].

Hospital mortality rate was 14%, lower than described by previous authors that considered only patients admitted into ICU \[[@CR2]\].

In general, predictors of long-term mortality found in this study are similar to those from other studies, like: age \[[@CR20], [@CR23]--[@CR27]\], comorbidities \[[@CR19], [@CR20], [@CR23]--[@CR26]\], functional status \[[@CR23]\], severity of infection \[[@CR20], [@CR23]\], SAPS II, positive blood cultures and infection by an ESKAPE pathogen. The association of an infection by a pathogen from the ESKAPE group with long-term mortality has not been described previously, as far as the authors are aware.

One surprising result was the fact that inappropriate antibiotic therapy was not retained as an independent prognostic factor, although this was shown to influence long-term mortality following bacteraemia \[[@CR20], [@CR23]\], but given the high proportion of patients that received appropriate antibiotic therapy in the first 24 h its impact in this cohort may be less evident.

In patients that survived hospital admission the infection-related risk factors were less significant, aside from positive blood cultures, and patient related factors were more relevant like age, comorbidities and functional status.

In the acute setting it is reasonable to expect infection to be the dominant cause of death. However in long-term mortality infection may play less of a direct role. Maybe it can be due to a combination of pre-existing co-morbidities, intensities of therapy (and its iatrogenic effects) the nature and severity of initial infection and the complications of the acute disease. Therefore the mechanism by which certain risk factors independently affect long-term prognosis should be investigated \[[@CR17]\]. Another important question is whether prevention or optimal management of these parallel conditions might reduce the long-term death rates \[[@CR19]\]. If post-sepsis long-term outcomes are primarily driven by the trajectory of pre-morbid conditions, then interventions targeted at complications attributed to critical illness may not be effective \[[@CR28]\]. However all risk factors related to long-term mortality should be considered when addressing individual prognosis and making clinical decision.

This study has several limitations. It is a single center study and although the study design was prospective, data regarding 5 year outcome was collected retrospectively, leading to the exclusion of a minority of patients; nevertheless the final database was of very good quality \[[@CR29]\]. We did not have a control population (general population or non-infected sample) to determine the true impact of severe infection. We did not collect data on the ultimate cause of death which would have been very important to identify modifiable prognostic factors that could improve long term outcomes. Secondly, we defined long-term mortality being a 5-year period as there is no consensus towards the definition of long-term outcomes. Finally, we have only studied one long-term outcome leaving others behind (namely those related to quality of life).

Our study has also several strengths; it includes a large cohort of patients, from different hospital settings, with different focus of infection. Previous studies have been restricted to intensive care patients \[[@CR2], [@CR4]--[@CR9]\], specific focus of infection \[[@CR20], [@CR25], [@CR27]\] or specific pathogens \[[@CR21], [@CR24]\].

Conclusions {#Sec9}
===========

Age, cancer, comorbidities, functional status (Karnovsky Index \< 70), SAPS II, severity of infection, positive blood cultures, and infection by a pathogen from the ESKAPE group were independently associated with increased 5-year mortality in this large group of patients with severe infection.

We hope that this information will help in the discussion of individual prognosis and clinical decision making.
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